| Cell line name |
MDA-MB-468rERI50 |
|---|
| Synonyms |
MDA-MB-468 rEribulin100 |
|---|
| Accession |
CVCL_D6VS |
|---|
| Resource Identification Initiative |
To cite this cell line use: MDA-MB-468rERI50 (RRID:CVCL_D6VS) |
|---|
| Comments |
Group: Triple negative breast cancer (TNBC) cell line.
Population: African American.
Selected for resistance to: ChEBI; CHEBI_63587; Eribulin (Halaven).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
- Mutation; HGNC; HGNC:9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Breast adenocarcinoma (NCIt: C5214) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0419 (MDA-MB-468) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
51Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=40300663; DOI=10.1016/j.canlet.2025.217754
Helen E. Grimsley, Magdalena Antczak, Ian G. Reddin, Nicole Weiler, Katie-May McLaughlin, Florian Rothweiler, Johannes Haas, Andrea Nist, Marco Mernberger, Thorsten Stiewe, Tim R. Fenton ...Show all 19 authors... , Daniel Speidel, Catherine Harper-Wynne, Karina Cox, Dirk Heckl, Jindrich Cinatl Jr., Mark N. Wass, Michelle D. Garrett, Martin Michaelis; Show fewer authors
Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.
Cancer Lett. 624:217754.1-217754.14(2025) |
|---|
| Entry history |
|---|
| Entry creation | 10-Sep-2024 |
|---|
| Last entry update | 14-Aug-2025 |
|---|
| Version number | 3 |
|---|
